Innovative Disease Management Models and Therapeutic Solutions Unveiled at the 5th China International Import Expo

At the Fifth China International Import Expo being held here, all parties are presenting optimized disease diagnosis and treatment management models as well as innovative treatment solutions.

 

Reporter learned on the 6th during an interview that the innovative integrated diagnosis and treatment model for fundus diseases — the one-stop vitreous cavity injection base project — has been launched, which aims to solve the three major problems faced by fundus disease patients: "difficulty in making appointments, complicated procedures, and long waiting times"; the "Standardized Diagnosis and Treatment Project for Hereditary Angioedema" has also been initiated, hoping that by 2025, 100 hereditary angioedema diagnosis and treatment centers will be established and a collaborative diagnosis and treatment network will be formed to shorten the medical visit paths of patients with rare diseases and improve their quality of life.

 

Novartis Innovative Drugs China is the supporter of the one-stop intravitreal injection base project. Wang Jia, Head of Ophthalmology, Transplantation, and Central Nervous System Therapeutic Areas at Novartis Innovative Drugs China, stated that they will continue to strengthen dialogue and communication with China's medical ecosystem through the platform of the CIIE, thereby providing patients with more and better solutions.

 

FundusDiseaseIs an important irreversible blinding eye disease. "Fundus diseases not only cause significant damage to visual function, but their progression is also irreversible, requiring long-term treatment. If patients cannot receive standardized diagnosis and treatment to delay the progression of the disease, they will eventuallyVision"Damaged, or even blindness." Professor Xu Xun, head of the Ophthalmic Fundus Disease Group of the Chinese Medical Association, stated, "The long-term treatment of chronic diseases requires convenience for patients and efficient operation of ophthalmology departments. Only by continuously optimizing medical service models and processes, and improving efficiency, can the best treatment outcomes be achieved."

 

"Intravitreal injection" is one of the important treatment methods for ophthalmic diseases. By injecting drugs directly into the vitreous cavity of the eye, the drugs can reach the lesion fastest to achieve rapid and effective treatment. It has become one of the most common intraocular operations worldwide.

 

"One-Stop Intravitreal Injection Base Project" can reshape multiple processes such as appointment scheduling, examination, and follow-up visits through informatization, significantly shortening and optimizing the service process. It reduces the waiting time for patients' injections from two weeks to half a day, achieving injection within 24 hours. Professor Wei Wenbin, chairman of the Ophthalmology Committee of the China Ambulatory Surgery Alliance, told reporters that in the past, patients receiving treatment for fundus diseases needed to visit the doctor repeatedly for consultation, examination, injection, and follow-up.HospitalThree or four times. "Through this project, we hope to implement morning outpatient visits and afternoon injections in most hospitals across China, completing the entire process from diagnosis to treatment within 24 hours."

 

The project model is jointly led by the Ocular Fundus Disease Group of the Chinese Medical Association and the Ophthalmology Committee of the China Ambulatory Surgery Alliance. Professor Li Xiaoxin, the Chief Superintendent of Xiamen Eye Center affiliated to Xiamen University, Professor Xu Xun, the leader of the Ocular Fundus Disease Group of the Chinese Medical Association, and Professor Wei Wenbin, the chairman of the Ophthalmology Committee of the China Ambulatory Surgery Alliance, are the academic leaders who jointly initiated the project. It plans to achieve the operation of over a thousand "one-stop vitreous cavity injection bases" in China after 2-3 years of efforts, empowering more than 10,000 ophthalmic medical professionals and benefiting over a million patients with fundus diseases.

 

In fact, the day surgery model has become an important part of the comprehensive reform of public hospitals. The one-stop intravitreal injection model has improved the efficiency of medical resource utilization, promoted the development of outpatient and day surgeries, and further freed up precious doctor resources. Zhang Ying, President of Novartis Innovative Drugs China, hopes this will bring more convenient, higher-quality, and more efficient diagnosis and treatment experiences to Chinese patients with fundus diseases.

 

Hereditary Angioedema is a rare autosomal dominant genetic disorder. Most patients experience unpredictable attacks, with high frequency and mostly moderate to severe episodes. When laryngeal edema occurs, the condition progresses rapidly, and if not treated promptly, it can lead to suffocation and death within 4.6 hours. Reporters learned that Takeda China, in collaboration with the China Rare Disease Alliance, launched the "Standardized Diagnosis and Treatment Project for Hereditary Angioedema" at this year's CIIE. Mr. Guohong Shan, Global Senior Vice President of Takeda Pharmaceuticals and President of Takeda China, expressed his hope to actively unite all parties, empower key drivers within the industry, and gradually form an innovative rare disease ecosystem centered around patients, which operates autonomously yet remains interconnected and mutually reinforcing.

 

Li Lin Kang, Chairman of the Chinese Rare Disease Alliance, told reporters: "Today, China's diagnostic and treatment capabilities for Hereditary Angioedema have far surpassed the past; we look forward to the Rare Disease Alliance and all sectors of society jointly promoting the 'Hereditary Angioedema Standardized Diagnosis and Treatment Project', so that every patient with Hereditary Angioedema can receive timely, accurate diagnosis and effective treatment."

 

At the CIIE exhibition site, the reporter saw a Clinical Decision Support System (CDSS) developed under the leadership of Professor Zhi Yuxiang, Chief Physician of the Allergy Department at Peking Union Medical College Hospital. This system will initiate new explorations in digital solutions for the clinical diagnosis of Hereditary Angioedema (HAE). "The CDSS system will rapidly transition from 'concept' to 'value.' Clinically, it can screen high-risk HAE patients through a data filtering model, reducing 'missed diagnoses,' thereby empowering clinicians in their diagnostic and treatment decisions," said Professor Zhi Yuxiang.

 

It is also reported that at last year's CIIE, Takeda Pharmaceutical signed an agreement with the China Rare Disease Alliance, Beijing Rare Disease Diagnosis and Treatment and Security Association, and the China Hemophilia Collaboration Group to launch the "100% Navigation" Hemophilia Multidisciplinary Diagnosis and Treatment Capacity Improvement Project. It is reported that since the project was launched a year ago, more than 700Famous DoctorThe training and coaching have promoted the construction of China's three-level hemophilia diagnosis and treatment system and the improvement of diagnostic and treatment standards.

 

Moreover, at this year's CIIE, the "rare bleeding and coagulation innovation drug family," including several innovative drugs, the upgraded version of the management tool supporting hemophilia pharmacokinetics (PK)-guided therapy: myPKFiT 3.0, and the innovative drug Maribavir for post-transplant CMV (cytomegalovirus) treatment, made their debut together, further instilling confidence in the improvement of patients' quality of life. (End)